JPM China Voice! What wonderful content does Huang Medicine and Reding Medicine bring?

The high-profile 39th J.P. Morgan Healthcare Conference is underway.
the JPM conference, we also saw a lot of Chinese biopharmaceutical companies.
today, we combine public information to show you what the presentation PPT of Huang Medicine, Reding Pharmaceuticals, Legendary Bio has presented.
and Yellow Pharma: In 2020/2021, five NDA sessions are expected for the three major products, and Yellow Pharma presents the latest developments and research plans for the company's three main products (Sevotinib, Sofantinib, and pyriquine) and re-introduces the company's four drugs in the early clinical stage.
, according to the report, and Huang Pharmaceutical products pipeline currently has 12 independent research and development of innovative drugs.
that in 2020/2021, five new drug listing applications and eight registration studies are expected to be submitted for the three major products of Huang Medicine.
savolitinib, formerly named Volitinib, is a powerful and highly selective oral small molecule MET inhibitor, and Yellow Medicine and AstraZeneca are developing the drug worldwide.
In China, the new drug listing application (NDA) for the treatment of non-small cell lung cancer of intersupcharged endocial conversion factor (MET) exon 14 has been accepted by the State Drug Administration (NMPA) of China and has been included in the priority review.
a study of non-small cell lung cancer patients with MET exon 14 jumps showed that the objective remission rate (ORR) of Sevotini monotherapy was 49.2% and the disease control rate (DCR) was 93. 4%; In patients with pulmonary sarcoma-like cancer (PSC) subtypes, THE ORR was 16.5%, the medium progression-free lifetime (mPFS) was 2 months, and the medium total survival (mOS) was 6.3 months.
same time, and Huang Medicine and AstraZeneone are exploring the effects of the combined treatment of EGFR-TKI incurable NSCLC.
addition to non-small cell lung cancer, Severtini's global development program includes kidney, stomach and colorectal cancers.
surufatinib, a new tyrosine kinase inhibitor, has been approved in China for the treatment of neuroendocrine tumors (NET) from non-pancreatic sources, and applications for new adaptations for the treatment of late pancreatic NET have also been accepted by NMPA.
same time, and Yellow Medicine has begun rolling the submission of Sovantinib to the FDA for the treatment of pancreas and non-pancreatic NET NDA.
According to newly disclosed data, in a Phase 3 study of non-pancreatic NET patients in China, the mPFS was 9.2 months in patients in the Sofantini group, well above the 3.8 months in the placebo group, reducing the risk of disease progression or death by 67 In a Phase 3 study of Pancreatic NET patients in China, Soventini increased the patient's mPFS by more than three times (10.9 months VS 3.7 months), reducing the risk of disease progress or death by 51%.
In addition to neuroendocrine tumors, the development plan for sorfantinib includes exploring the effects of sovantinib monotherapy for bile dubious cancer and soft tissue sarcoma, as well as the effectiveness of Sovantini in the treatment of solid tumors in a joint PD-1 monoanti (Terripri monoanti, syndicated monoanti, and terraeliju monoanti).
In a Phase 2 study of G3 neuroendocrine tumors (NET)/neuroendocrine cancer (NEC), 250 mg of Sovantinie/Tripley monoantitherapy achieved 64% ORR (n-11), 100% DRR, and showed good tolerance.
is a highly selective and powerful oral VEGFR inhibitor that has been approved in China for the treatment of metastatic colorectal cancer.
currently, and yellow medicine is exploring the therapeutic potential of pyriquine worldwide.
the company has launched a phase 3 registered study of FRESCO-2 in patients with metastatic colorectal cancer in the United States, Europe and Japan.
FDA has granted fast-track eligibility for the treatment of metastatic colorectal cancer.
According to the report, the development plan for jaundial medicine also includes gastric and breast cancer, as well as the exploration of the effects of a combination of pyriquine and PD-1 monoantigen (Cindili monoanti, Jeno monoanti, terreliju monoanti) to treat solid tumors.
conference, and Huang Pharma also highlighted four early clinical development stage products, namely: Syk inhibitor HMPL-523, PI3K inhibitor HMPL-689, FGFR 1/2/3/inhibitor HMPL-453, IDH1/2 inhibitor HMPL-306.
currently, and Huang Medicine is developing these drugs in research around the world, involving inert NHL, B-cell malignancies, mesothelioma, intra-hepatic bile duodenal cancer, blood malignancies and so on.
and Yellow Pharmaceuticals are currently driving a high-value and differentiated portfolio of 12 innovative drugs developed independently.
addition to the above products, these products include several preclinical drug candidates.
, according to the JPM report, and Yellow Pharmaceuticals plans to develop these products worldwide for the benefit of a wide range of patients around the world.
: is entering the stage of accelerating growth At this JPM conference, Ding Pharmaceuticals spoke at 11:40 a.m. Eastern Time on January 12.
recently, Redding Pharmaceuticals has worked with Cullinan Oncology, argenx and Turning Point Therapeutics to obtain exclusive development and commercialization rights for EGFR inhibitors CLN-081, FcRn targeted therapies efgartigimod and MET/SRC/CSF1R inhibitors TPX-0022 in Greater China, respectively.
, all three assets have potential "best-in-class" or "first-in-class" properties, and are targeted at a large number of unsolt disease treatment areas in China and around the world.
through external introduction and in-house research and development, Redding Pharmaceuticals currently has 21 assets in the pipeline, 10 of which are in the late stages, 5 have been approved in the United States and 7 in-house development assets have global rights.
In China, PARP inhibitor Nirapali (Nerapali) and tumor electric field treatment products (Epdone) have been commercialized, and kit/PDGFR alpha kinase inhibitors Ripatini and new antibiotic NUZYRA have been listed in China as priority reviews.
the therapeutic field, Reding Pharmaceuticals focuses on unsealed major medical needs and potentially effective combination therapies.
's recent collaboration has further expanded its product pipeline in the areas of stomach cancer, lung cancer and autoimmune diseases in China.
, reding's bemarituzumab (targeting FGFR2b), margetuximab (targeting HER2), and TPX-0022 cover approximately 50% of gastric cancer patients.
addition, the company is also targeted to develop differentiated lung cancer treatment portfolios such as repotrectinib, CLN-081, TPX-0022, and the introduction of efgartigimod has further enriched its autoimmune disease product pipeline.
, founded in 2014, is at an inflection point in accelerating growth, according to the report, and the company aims to enter a new phase after 2023 as the world's leading biopharmaceutical company.
company will use its in-house capabilities and global network to help drive the next wave of healthcare innovation, bringing more innovative therapies to patients in China and around the world.
Legendary Creatures: CAR-T Therapy Cilta-cel is expected to receive FDA approval this year Legendary Creatures will present the company's latest developments at the JPM Conference on January 13 at 4:30 p.m. ET.
legend made a name for it at the 2017 ASCO Annual Meeting with its excellent data on CAR-T therapy and was listed on NASDAQ in June 2020.
the company's global partnership with Janssen to develop ciltacabtagene autoleucel, a CAR-T therapy targeted at BCMA, known as cilta-cel, was established in December 2017 and has so far received $350 million in upfront payments and milestone payments totalling $110 million, according to a JPM report released by Legendary Creatures.
currently, the most notable data in the legendary bioinnova pipeline is that the main candidate drug, cilta-cel, may have the potential to provide a far-reaching and long-lasting anti-tumor response in relapsed/refractive multiple myeloma (RR MM).
has also established a broad portfolio of drug candidates for blood and solid cancers, ranging from autobiographic TOT to allogeneic CAR-T.
MM is a highly unsecured blood cancer with high clinical needs, with very poor survival rate of relapsed/re treatable MM and a medium OS of less than 12 months.
phase 1 clinical trial in China called LEGEND-2 shows that cilta-cel has long-term depth response and high response rates in RR MM patients, with ORR up to 88% and mPFS for more than 18 months.
1b/2 trial, called CARTITUDE-1, showed that the medium follow-up time was 12.4 months, mPFS was not reached, and the 12-month PFS and OS rates were 76.6% and 88.5%, respectively.
December 2020, cilta-cel has begun rolling the submission of a Biological Products Licensing Application (BLA) at the FDA, which is expected to be approved in the second half of 2021.
addition, legendary creatures have the goal of submitting a cilta-cel listing license application (MAA) in Europe in the first half of 2021, a China BLA in the second half, and regulatory approval in Europe and China in 2022.
, Legendary Creatures will begin phase 1 research on T-cell lymphoma in the U.S. in 2021 with LB1901, a CAR-T therapy targeted at CD4.
, according to JPM, Legendary Creatures is building a bridge between East and West in cell therapy around the world.
driven by clinical needs, they will continue to develop cell therapies to fulfill their mission to improve the lives of patients around the world.